Published in Cancer Weekly, March 9th, 1998
Under the terms of the collaboration, Nippon Kayaku provides research funding to Signal for the initial two years of the agreement, and continues to conduct animal pharmacology studies of compounds generated by the collaboration. Signal performs combinatorial chemistry and use its proprietary human neuronal cell lines to further optimize the compound and characterize its mechanism of action prior to the start of clinical studies.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.